Cortland Associates Inc. MO Trims Position in Danaher Co. (NYSE:DHR)

Cortland Associates Inc. MO cut its holdings in Danaher Co. (NYSE:DHR) by 1.1% during the 4th quarter, Holdings Channel reports. The firm owned 171,882 shares of the conglomerate’s stock after selling 1,841 shares during the period. Danaher makes up approximately 4.5% of Cortland Associates Inc. MO’s investment portfolio, making the stock its 9th biggest position. Cortland Associates Inc. MO’s holdings in Danaher were worth $39,455,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of DHR. Decker Retirement Planning Inc. bought a new stake in Danaher during the 4th quarter valued at approximately $31,000. Teachers Insurance & Annuity Association of America bought a new stake in Danaher during the 3rd quarter valued at approximately $39,000. MidAtlantic Capital Management Inc. bought a new stake in Danaher during the 3rd quarter valued at approximately $40,000. FSA Wealth Management LLC bought a new stake in Danaher during the 3rd quarter valued at approximately $50,000. Finally, Darwin Wealth Management LLC bought a new stake in Danaher during the 3rd quarter valued at approximately $55,000. 79.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. KeyCorp lifted their price objective on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Royal Bank of Canada lowered their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Jefferies Financial Group lowered their target price on shares of Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a report on Wednesday. Stifel Nicolaus lifted their target price on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a report on Wednesday, October 23rd. Finally, UBS Group lowered their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $284.14.

Danaher Trading Down 10.0 %

Shares of DHR stock opened at $223.12 on Thursday. Danaher Co. has a 12-month low of $223.00 and a 12-month high of $281.70. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The stock’s 50-day moving average price is $236.09 and its 200-day moving average price is $253.66. The stock has a market capitalization of $161.15 billion, a price-to-earnings ratio of 42.58, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting the consensus estimate of $2.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. During the same period last year, the company earned $2.09 earnings per share. Equities research analysts predict that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.48%. Danaher’s payout ratio is 20.61%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.